New hope pill tested for Tough-to-Treat lung cancer
NCT ID NCT07361237
Summary
This early-stage study is testing a new oral medication called HJ-004-02 for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and get a first look at whether it can shrink tumors. It will enroll about 36 adults who have run out of other effective options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.